Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717403 | 0.94 | AR (0.35) | ARPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL26842628 | 0.92 | HTR1A (0.34) | AR | |
| SCHEMBL22845199 | 0.91 | LMNA (0.37) | — | |
| SCHEMBL22845418 | 0.91 | PRLHR (0.34) | ARPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL22845200 | 0.87 | GCGR (0.38) | — | |
| SCHEMBL26842631 | 0.85 | AR (0.32) | AR | |
| SCHEMBL22845536 | 0.85 | MAPK14 (0.34) | CSNK1DCSNK1E | |
| SCHEMBL22845309 | 0.85 | MAPK14 (0.34) | PRKAA2 | |
| SCHEMBL22845318 | 0.85 | PRLHR (0.33) | ARPRKAA2PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL22830598 | 0.85 | GPR119 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | AR 912/4885PRKAA2 2338/4885PRKAB2 3351/4885 |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | AR 912/4885PRKAA2 2338/4885PRKAB2 3351/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | AR 912/4885PRKAA2 2338/4885PRKAB2 3351/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | AR 912/4885PRKAA2 2338/4885PRKAB2 3351/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | AR 912/4885PRKAA2 2338/4885PRKAB2 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.